<DOC>
	<DOC>NCT01108809</DOC>
	<brief_summary>The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. The study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.</brief_summary>
	<brief_title>Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Inclusion criteria: diagnosis of essential arterial hypertension (BP&gt;140/90 mm HG or BP&gt;130/80 mm Hg for diabetic patients) at least one additional cardiovascular risk factor and/or known single or multiple end organ damage and/or previous cardiovascular disease Exclusion criteria: hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market, as prescribed in the SPC pregnancy and lactation diseases involving biliary obstruction severe liver impairment severe hypertension malignant hypertension secondary hypertension patients age under 18 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>